Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran
Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. Methods: A literature search was conduc...
محفوظ في:
| المؤلف الرئيسي: | Kuyumjian, Yara (author) |
|---|---|
| مؤلفون آخرون: | Miyares, Marta A. (author), Eaves, Shannon (author) |
| التنسيق: | article |
| منشور في: |
2015
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6127 http://dx.doi.org/10.1177/0897190015615248 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.sagepub.com/doi/pdf/10.1177/0897190015615248 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Idarucizumab for Reversal of Dabigatran
حسب: Sheikh‑Taha, Marwan
منشور في: (2019) -
Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury
حسب: Sheikh-Taha, Marwan
منشور في: (2018) -
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
حسب: Shahd Abubaker Elamin (22569539)
منشور في: (2025) -
Novel Federated Decision Making for Distribution of Anti-SARS-CoV-2 Monoclonal Antibody to Eligible High-Risk Patients
حسب: AlSereidi, Abeer
منشور في: (2022) -
Federal Multi Criteria Decision Making Framework in Distribution of Anti-SARS-CoV-2 Monoclonal Antibody to Eligible High-Risk Patients as Case Study
حسب: ALSEREIDI, ABEER
منشور في: (2022)